SCHEMBL29689484

SCHEMBL29689484

COc1cc(C)c(F)cc1C(C)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 7/20 0.48
PTGS1 P23219 5/20 0.48
POLB P06746 2/20 0.44
TSHR P16473 2/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
AKR1C3 P42330 9/20 0.43
AKR1C2 P52895 9/20 0.43
APP P05067 1/20 0.40
CYP2C19 P33261 1/20 0.40
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
CDC42 P60953 1/20 0.36
RAC1 P63000 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16386818 0.79 POLB (0.59) POLBTSHRMAPTHPGDHSD17B10
SCHEMBL30824278 0.79 PTGS2 (0.55) PTGS2PTGS1POLBTSHRMAPT
SCHEMBL490436 0.79 PTGS2 (0.55) PTGS2PTGS1POLBTSHRMAPT
SCHEMBL195368 0.79 POLB (0.55) PTGS2PTGS1POLBTSHRMAPT
SCHEMBL3678216 0.78 PTGS2 (0.48) PTGS2PTGS1POLBTSHRMAPT
SCHEMBL24211162 0.76 GAA (0.43) POLBTSHRMAPTHPGDHSD17B10
SCHEMBL19182904 0.75 PTGS2 (0.49) PTGS2PTGS1TSHRAKR1C3AKR1C2
SCHEMBL31170887 0.75 PTGS2 (0.49) PTGS2PTGS1TSHRAKR1C3AKR1C2
SCHEMBL22457320 0.75 PTGS2 (0.60) PTGS2PTGS1TSHRAKR1C3AKR1C2
SCHEMBL22796714 0.73 POLB (0.41) POLBGAAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351577-B2 Inhibiting cyclic AMP-responsive element-binding protein (CREB) FORMA THERAPEUTICS, INC. (US) 2025-07-08 US disclosed
US-20250188079-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) FORMA THERAPEUTICS, INC. 2025-06-12 US disclosed
US-20220213089-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) FORMA THERAPEUTICS, INC. 2022-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188079-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) CREBBP, CREB1, EP300 PTGS2 2496/4885PTGS1 1831/4885POLB 731/4885
US-12351577-B2 Inhibiting cyclic AMP-responsive element-binding protein (CREB) CREBBP, CREB1, EP300 PTGS2 2496/4885PTGS1 1831/4885POLB 731/4885
US-20220213089-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) CREBBP, CREB1, EP300 PTGS2 2496/4885PTGS1 1831/4885POLB 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.